When it comes to caring for children, New Jersey offers several children’s hospitals equipped with state-of-the-art ...

Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development. The trial evaluated Cobnefy as an add-on ...

(Reuters) -Bristol Myers Squibb reported better-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio of drugs that spur a patient's ...

Bristol Myers Squibb shares were falling Thursday despite a first-quarter financial report that beat expectations amid ...

on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric patients (12 years and older) with ...

Bristol Myers Squibb on Thursday beat first-quarter estimates and hiked its revenue and profit guidance for the year, as the drugmaker cuts costs. The company now expects 2025 revenue to come in ...

April 24 (Reuters) - Bristol Myers Squibb (BMY.N), opens new tab reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to growth from its portfolio ...